Fresenius disposes of Schiwa:
This article was originally published in Clinica
German dialysis specialist Fresenius is to sell Schiwa, its infusion solution manufacturer, to B Braun Melsungen. Fresenius bought Schiwa from BASF subsidiary Knoll in 1992 but met with opposition from the German Kartellamt (monopolies commission). The Kartellamt ruled in October last year that the merger would lead to an overly dominant position in the German infusion and dialysis products market (see Clinica No 678, p 15).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.